$MYSTMYST Precio

On August 23, Cathie Wood's ARK Invest released its weekly market report covering three major themes: AI agents will continue to drive the growth of Anthropic and OpenAI. Anthropic submitted an S-1 draft to the SEC on June 1 in preparation for a potential IPO and has been engaging with investors to gauge market sentiment. As of the end of May, Anthropic's annual recurring revenue (ARR) had reached $47 billion, starting from about $9 billion in early 2026, growing more than fivefold in just five months; data provider TickerTrends estimates its current ARR may exceed $74 billion. OpenAI's ARR is approximately $41 billion, doubling from about $20 billion at the beginning of the year. Together, the two companies' ARR has surpassed $115 billion, exceeding the combined 12-month revenue of SAP, Salesforce, and Adobe, and approaching Microsoft’s productivity and business processes segment's annual run rate of about $150 billion. Both companies plan to finance large-scale computing infrastructure through the public markets. Grok 4.6 may further drive down the cost curve for cutting-edge AI: SpaceXAI's Grok 4.6 is designed for programming, agent tasks, and knowledge work, with key parameters including a 500,000 token context window, input costs of $2 per million tokens, and output costs of $6 per million tokens, significantly lower than OpenAI's GPT-5.6 Sol ($30 per million tokens) and Anthropic's Claude Fable 5 ($50 per million tokens). Artificial Analysis assesses its Intelligence Index score at 61, on par with GPT-5.6 Sol, trailing Claude Opus 5 and Fable 5 by about 1 to 2 points, but at a much lower price. In terms of task costs, Grok 4.6 is about $0.84 per task, sitting at the intelligent-cost Pareto frontier; the AA-Briefcase long-term agent knowledge work Elo score is 1577, roughly equal to Claude Fable 5's 1574. SpaceXAI also launched Grok Bot, extending competition from model performance to agent software layers capable of running tasks for extended periods. With improvements in model capabilities, cost metrics should shift from 'price per token' to 'price per completed task.' If training and inference costs continue to decline by 85% and 99.9% annually, respectively, enterprises will deploy agents in more workflows, significantly accelerating AI adoption. Minimal Residual Disease (MRD) detection proves its utility and continues to scale: Key evidence comes from bladder cancer trials IMvigor010 and IMvigor011, where ctDNA positive patients showed a 50% improvement in median overall survival after using atezolizumab. Natera's Signatera sales reached 283,000 last quarter (an increase of 34,000), while all other solid tumor MRD tests combined totaled only 41,000, giving Natera about 87% market share in the solid tumor MRD space. Signatera is expected to reach approximately $1.5 billion in revenue by its fifth year, about twice that of Cologuard during the same period. The market consensus opportunity is around $20 billion, with monitoring of cancer survivors, late-stage treatment monitoring, CAR-T, and global expansion potentially further scaling the market.

On August 23, Cathie Wood's ARK Invest released its weekly market report covering three major themes: AI agents will continue to drive the growth of Anthropic and OpenAI. Anthropic submitted its S-1 draft to the SEC on June 1 in preparation for a potential IPO and has been engaging with investors to gauge market sentiment. As of the end of May, Anthropic's annual recurring revenue (ARR) reached $47 billion, starting from approximately $9 billion in early 2026, growing more than fivefold in just five months; data provider TickerTrends estimates its current ARR may exceed $74 billion. OpenAI's ARR is about $41 billion, roughly double the $20 billion at the beginning of the year. Together, the two companies have an ARR exceeding $115 billion, surpassing the combined 12-month revenue of SAP, Salesforce, and Adobe, and nearing Microsoft’s productivity and business processes division's annual run rate of about $150 billion. Both companies plan to finance large-scale computing infrastructure through public markets. Grok 4.6 may further drive down the frontier AI cost curve: Released by SpaceXAI, Grok 4.6 is designed for programming, agent tasks, and knowledge work, with key parameters including a 500,000 token context window, input costs of $2 per million tokens, and output costs of $6 per million tokens, significantly lower than OpenAI's GPT-5.6 Sol ($30) and Anthropic's Claude Fable 5 ($50). Artificial Analysis assessed its Intelligence Index score at 61, on par with GPT-5.6 Sol, trailing Claude Opus 5 and Fable 5 by about 1 to 2 points but at a much lower price. In terms of task costs, Grok 4.6 is approximately $0.84 per task, placing it at the smart-cost Pareto frontier; AA-Briefcase's long-term agent knowledge work Elo score is 1577, roughly equal to Claude Fable 5's 1574. SpaceXAI also launched Grok Bot, expanding competition from model performance to agent software layers capable of running tasks over extended periods. As model capabilities improve, cost measures should shift from 'per token price' to 'per completed task price.' If training and inference costs continue to decline by 85% and 99.9% annually, respectively, businesses will deploy agents in more workflows, significantly accelerating AI adoption. Minimal Residual Disease (MRD) detection proves its utility and continues to scale: Key evidence comes from bladder cancer trials IMvigor010 and IMvigor011, where ctDNA positive patients showed a 50% improvement in median overall survival after using atezolizumab. Natera's Signatera sales reached 283,000 last quarter (an increase of 34,000), while all other solid tumor MRD tests combined totaled only 41,000, giving Natera approximately 87% market share in solid tumor MRD. Signatera is expected to achieve around $1.5 billion in revenue in its fifth year, about double that of Cologuard during the same period. The market consensus opportunity is around $20 billion, with monitoring for cancer survivors, advanced treatment monitoring, CAR-T, and global expansion potentially further scaling the market.

According to Bitcoin.com News, U.S. Senator Kirsten Gillibrand stated that Congress should prohibit the president, their spouses, and senior officials from issuing, initiating, or profiting from cryptocurrency during their terms, and incorporate this ethical ban into the Digital Asset Market Structure Act. A survey revealed that 63% of respondents believe that the cryptocurrency profits of Trump and his family are inappropriate. Trump disclosed in his annual report that cryptocurrency-related income exceeded $1.4 billion in 2025. The controversy extends to the Senate's Digital Asset Market Clearity Act, which is set for its first procedural vote in the Senate on September 15. Kirsten Gillibrand indicated that she would not support allowing the president to profit from public office with taxpayer backing.